# G1 Therapeutics, Inc.

G1 Therapeutics, Inc. is a company headquartered in Research Triangle Park, NC, United States.

## Company overview

- **Legal name:** G1 Therapeutics, Inc.
- **Former names in filing history:** G-Zero Therapeutics, Inc. (2012-10-12 to 2013-04-18)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Research Triangle Park, NC, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001560241

## About

G1 Therapeutics, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001560241, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2024-02-28, it reported annual revenue of USD 82,511,000; net income of USD -47,967,000; total assets of USD 121,540,000 for the fiscal period ended 2023-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2023 (period ended 2023-12-31)

- **Revenue:** $82.5M (USD 82,511,000)
- **Net income:** -$48.0M (USD -47,967,000)
- **Total assets:** $121.5M (USD 121,540,000)
- **Cash and equivalents:** $32.2M (USD 32,218,000)
- **Operating cash flow:** -$38.3M (USD -38,337,000)

### FY2022 (period ended 2022-12-31)

- **Revenue:** $51.3M (USD 51,301,000)
- **Net income:** -$147.6M (USD -147,559,000)
- **Total assets:** $188.0M (USD 187,965,000)
- **Cash and equivalents:** $94.6M (USD 94,594,000)
- **Operating cash flow:** -$128.6M (USD -128,620,000)

### FY2021 (period ended 2021-12-31)

- **Revenue:** $31.5M (USD 31,476,000)
- **Net income:** -$148.4M (USD -148,352,000)
- **Total assets:** $254.1M (USD 254,094,000)
- **Cash and equivalents:** $221.2M (USD 221,186,000)
- **Operating cash flow:** -$132.1M (USD -132,108,000)

### FY2020 (period ended 2020-12-31)

- **Revenue:** $45.3M (USD 45,285,000)
- **Net income:** -$99.3M (USD -99,254,000)
- **Total assets:** $228.6M (USD 228,552,000)
- **Cash and equivalents:** $207.3M (USD 207,306,000)
- **Operating cash flow:** -$83.7M (USD -83,742,000)

## Recent SEC filings

- Form 8-K — filed 2024-09-18 — period 2024-09-18 — 8-K
- Form SC 13G — filed 2024-08-19
- Form 10-Q — filed 2024-08-08 — period 2024-06-30 — 10-Q
- Form 8-K — filed 2024-08-08 — period 2024-08-08 — 8-K
- Form 8-K — filed 2024-08-07 — period 2024-08-06 — 8-K
- Form 8-K — filed 2024-06-24 — period 2024-06-24 — 8-K
- Form 8-K — filed 2024-06-14 — period 2024-06-13 — 8-K
- Form 10-Q — filed 2024-05-01 — period 2024-03-31 — 10-Q
- Form 8-K — filed 2024-05-01 — period 2024-05-01 — 8-K
- Form DEF 14A — filed 2024-04-25 — period 2024-06-13 — DEF 14A
- Form 8-K — filed 2024-03-22 — period 2024-03-21 — 8-K
- Form 10-K — filed 2024-02-28 — period 2023-12-31 — 10-K

---

Updated: 2026-10-23T20:10:52Z

Canonical page: https://altss.com/profile/g1-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology